98 related articles for article (PubMed ID: 2118418)
1. Mechanisms of cyclophosphamide action on hepatic P-450 expression.
LeBlanc GA; Waxman DJ
Cancer Res; 1990 Sep; 50(18):5720-6. PubMed ID: 2118418
[TBL] [Abstract][Full Text] [Related]
2. Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats.
LeBlanc GA; Sundseth SS; Weber GF; Waxman DJ
Cancer Res; 1992 Feb; 52(3):540-7. PubMed ID: 1732040
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
4. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation.
Clarke L; Waxman DJ
Cancer Res; 1989 May; 49(9):2344-50. PubMed ID: 2706622
[TBL] [Abstract][Full Text] [Related]
5. Female-predominant rat hepatic P-450 forms j (IIE1) and 3 (IIA1) are under hormonal regulatory controls distinct from those of the sex-specific P-450 forms.
Waxman DJ; Morrissey JJ; LeBlanc GA
Endocrinology; 1989 Jun; 124(6):2954-66. PubMed ID: 2785912
[TBL] [Abstract][Full Text] [Related]
6. Hepatic P450 expression in hypothyroid rats: differential responsiveness of male-specific P450 forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to thyroid hormone.
Ram PA; Waxman DJ
Mol Endocrinol; 1991 Jan; 5(1):13-20. PubMed ID: 2017188
[TBL] [Abstract][Full Text] [Related]
7. Feminization of rat hepatic P-450 expression by cisplatin. Evidence for perturbations in the hormonal regulation of steroid-metabolizing enzymes.
LeBlanc GA; Waxman DJ
J Biol Chem; 1988 Oct; 263(30):15732-9. PubMed ID: 3139676
[TBL] [Abstract][Full Text] [Related]
8. Induction of microsomal NADPH-cytochrome P-450 reductase and cytochrome P-450IVA1 (P-450LA omega) by dehydroepiandrosterone in rats: a possible peroxisomal proliferator.
Wu HQ; Masset-Brown J; Tweedie DJ; Milewich L; Frenkel RA; Martin-Wixtrom C; Estabrook RW; Prough RA
Cancer Res; 1989 May; 49(9):2337-43. PubMed ID: 2523237
[TBL] [Abstract][Full Text] [Related]
9. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels.
Chang TK; Chen H; Waxman DJ
Drug Metab Dispos; 1994; 22(5):673-9. PubMed ID: 7835216
[TBL] [Abstract][Full Text] [Related]
10. Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase.
Waxman DJ; Morrissey JJ; Leblanc GA
Mol Pharmacol; 1989 Apr; 35(4):519-25. PubMed ID: 2495435
[TBL] [Abstract][Full Text] [Related]
11. Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin.
Morgan ET
Mol Pharmacol; 1989 Nov; 36(5):699-707. PubMed ID: 2511427
[TBL] [Abstract][Full Text] [Related]
12. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro.
Murray M; Butler AM; Stupans I
J Pharmacol Exp Ther; 1994 Aug; 270(2):645-9. PubMed ID: 8071856
[TBL] [Abstract][Full Text] [Related]
13. Effects of the anticancer dehydrotarplatin on cytochrome P450 and antioxidant enzymes in male rat tissues.
Nannelli A; Messina A; Marini S; Trasciatti S; Longo V; Gervasi PG
Arch Toxicol; 2007 Jul; 81(7):479-87. PubMed ID: 17364183
[TBL] [Abstract][Full Text] [Related]
14. Peripubertal androgen imprinting of rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase: pretranslational regulation and impact on microsomal drug activation.
Chang TK; Bellward GD
J Pharmacol Exp Ther; 1996 Sep; 278(3):1383-91. PubMed ID: 8819526
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450.
Marinello AJ; Bansal SK; Paul B; Koser PL; Love J; Struck RF; Gurtoo HL
Cancer Res; 1984 Oct; 44(10):4615-21. PubMed ID: 6380709
[TBL] [Abstract][Full Text] [Related]
16. Interferon down regulates the male-specific cytochrome P450IIIA2 in rat liver.
Craig PI; Mehta I; Murray M; McDonald D; Aström A; van der Meide PH; Farrell GC
Mol Pharmacol; 1990 Sep; 38(3):313-8. PubMed ID: 1698250
[TBL] [Abstract][Full Text] [Related]
17. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.
Huang Z; Raychowdhury MK; Waxman DJ
Cancer Gene Ther; 2000 Jul; 7(7):1034-42. PubMed ID: 10917206
[TBL] [Abstract][Full Text] [Related]
18. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat.
Thummel KE; Schenkman JB
Mol Pharmacol; 1990 Jan; 37(1):119-29. PubMed ID: 2105452
[TBL] [Abstract][Full Text] [Related]
19. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
20. Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone.
Yeowell HN; Waxman DJ; LeBlanc GA; Linko P; Goldstein JA
Arch Biochem Biophys; 1989 Jun; 271(2):508-14. PubMed ID: 2499261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
